Alterity Therapeutics (ASX:ATH) completed the phase two trial of its drug candidate, ATH434, for patients with advanced multiple system atrophy, according to a Thursday Australian bourse filing.
The company completed the last patient visit in the trial, finishing all clinical evaluations, the filing said.
The company expects to report the data from the study in mid-2025, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.